Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
ORGANIZATION
JPMA President Opposes Annual NHI Price Revision
Masayo Tada, president of the Japanese Pharmaceutical Manufacturers Association (JPMA), voiced strong opposition to an annual revision of NHI drug prices on November 20, saying that the current biennial revision should be maintained. Pharmaceutical companies’ core businesses are based on…
To read the full story
ORGANIZATION
- JMA Renews Opposition to Insurance Review for OTC-Like Drugs
October 24, 2025
- MFN Drug Pricing Already Affecting 4 Firms’ R&D Plans in Japan, EFPIA Chief Flags Fallout
October 22, 2025
- JPMA Chief Hails Takaichi’s Election as PM, Calls for Stronger Innovation Ecosystem
October 22, 2025
- Wholesalers to Broaden Lobbying Push to Include Ishin amid Political Shift: Leader
October 17, 2025
- JPMA Chief Renews Call for Reflecting Inflation and Wage Hikes in Drug Pricing
October 17, 2025
Members of the Central Social Insurance Medical Council (Chuikyo) broadly agreed on October 17 that incentives under the medical fee…
Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…
In the dynamic pharmaceutical landscape, especially within the nuanced Japanese market, leadership hinges on acute awareness. This transcends surface-level observations, demanding a deep understanding of regulatory shifts, cultural sensitivities, and evolving patient needs. For leaders in this sector, particularly those…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…